Eli Lilly stock targets blood cancer with Calytrix deal
Published on 11/21/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLilly expands its cancer pipeline
- Eli Lilly agreed on November 17 to acquire Calytrix Bio in a deal worth up to 1.5 billion US dollars.
- The transaction adds a preclinical antibody targeting mutant calreticulin-driven blood cancers to Lilly's development portfolio.
- Lilly's stock traded below the previous Xetra close on Saturday, November 21.
Eli Lilly agreed on November 17, 2026, to acquire Calytrix Bio in a transaction valued at up to 1.5 billion US dollars. The agreement gives Lilly access to an investigational antibody aimed at cancers driven by mutant calreticulin, according to Pharmaceutical Technology.
Deal adds early oncology asset
Calytrix Bio is developing a biparatopic antibody for mutant calreticulin-driven essential thrombocythemia and myelofibrosis. The payment structure combines an upfront amount with additional cash tied to clinical and regulatory milestones, so the maximum transaction value depends on development progress.
The asset remains preclinical. Lilly will advance the program toward clinical development and broaden its presence in myeloproliferative neoplasms, a group of blood disorders that includes essential thrombocythemia and myelofibrosis.
Stock trades below Friday close
Eli Lilly stock traded at 1,228.10 euros on Lang & Schwarz at 11:28 CET on Saturday, November 21, 0.41 percent below the Xetra close of Friday, November 20.
Eli Lilly and Company
- ISIN: US5324571083
- Lang & Schwarz price: 1,228.10 euros on November 21, 2026, at 11:28 CET
- Xetra close: 1,233.20 euros on November 20, 2026
- Comparison: 0.41 percent below the Xetra close
- Week event: Calytrix Bio acquisition agreement announced November 17, 2026
US equity markets and major healthcare shares remain the broader setting for Lilly's European listing; see the Current market reports.
